LUPIN TO CONDUCT TRIALS OF PSORIASIS DRUG

A A

Lupin has received approval from the Drug Controller General of India for conducting Phase II clinical trials of its investigation new drug candidate LLL-3348 (Desoris), which is a proposed treatment of moderate-to-severe chronic stable plaque-type psoriasis.

The approval comes after the company's successful completion of the therapeutic evaluation and safety profiling of Desoris in Phase I single- and multiple-dose study in healthy volunteers. Desoris will now be evaluated for efficacy in patients in a Phase II clinical trial at 10 sites across India.